Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 06

1688P - Selection of PD-L1 escape variants in microsatellite stable metastatic colorectal cancer on avelumab treatment

Date

10 Sep 2022

Session

Poster session 06

Topics

Tumour Immunology;  Translational Research;  Immunotherapy

Tumour Site

Colon and Rectal Cancer

Presenters

Christoph Schultheiß

Citation

Annals of Oncology (2022) 33 (suppl_7): S758-S771. 10.1016/annonc/annonc1078

Authors

C. Schultheiß1, L. Claaß2, R. Scholz2, L. Paschold1, D. Simnica1, V. Heinemann3, S. Stintzing4, M. Binder1

Author affiliations

  • 1 Internal Medicine Iv - Oncology/hematology, Martin Luther University Halle-Wittenberg, 06120 - Halle (Saale)/DE
  • 2 Internal Medicine Iv - Hematology/oncology, Martin Luther Universität Halle-Wittenberg, 06120 - Halle (Saale)/DE
  • 3 Medical Oncology Dept. And Comprehensive Cancer Center, LMU Klinikum der Universität München, 81377 - Munich/DE
  • 4 Hematology, Oncology, And Tumor Immunology (ccm) Dept, Charité - Universitätsmedizin Berlin, 10117 - Berlin/DE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1688P

Background

In patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC), immune checkpoint blockade is ineffective. However, data from the AVETUX trial suggests PD-L1 epitope escape upon avelumab treatment in MSS-mCRC patients expressing the high affinity SNP of FcγR3a (rs396991).

Methods

Biomarker substudy of a patient on the FIRE-6 (AIO KRK-0118) trial with histologically confirmed, treatment-naïve, RAS/RAF wild-type metastatic colorectal cancer (MSS). The patient received 4 cycles of FOLFIRI/cetuximab, followed by 4 cycles FOLFIRI/cetuximab + avelumab, followed by avelumab maintenance treatment for 10 weeks until end of treatment (EOT) due to progression in week 19. Mutational profiling of cell-free DNA (cfDNA) was performed with custom gene panels and liquid biopsy monitoring by digital droplet PCR (ddPCR). Identified PD-L1 variants were functionally validated in cell culture models using standard molecular genetics tools.

Results

We confirmed the principle of PD-L1 immune escape in MSS-mCRC patients expressing the high affinity SNP of FcγR3a under avelumab treatment. In the monitored patient PD-L1 L88E and L88fs mutations emerged under selective pressure with avelumab. Functional validation of PD-L1 in cell models suggests that L88E represents a phosphomimetic variant of L88S identified in the AVETUX trial. Both variants exhibit loss of protein stability and proteasomal degradation.

Conclusions

PD-L1 mutations mediate subclonal immune escape to avelumab in some patients with mCRC expressing high-affinity FcγR3a. Leucine 88 of PD-L1 is a hotspot residue critically regulating PD-L1 cell surface expression with clinical significance in the context of immune checkpoint blockade. Together with the emergence of truncated PD-L1 variants, regulation of PD-L1 availabilty but not epitope disruption appears to be the key mechanistic principle towards PD-L1 escape. Future trials confirming this principle in other entities are warranted especially in patient subpopulations with rs396991.

Clinical trial identification

NCT05217069.

Editorial acknowledgement

Legal entity responsible for the study

AIO-Studien-gGmbH.

Funding

Has not received any funding.

Disclosure

V. Heinemann: Non-Financial Interests, Institutional, Invited Speaker: Merck, Amgen, Roche, Sanofi, Sirtex, Servier, Pfizer, Pierre-Fabre, AstraZeneca, BMS, MSD, Novartis, Boehringer Ingelheim, Celgene, Terumo, Oncosil, Seagen; Non-Financial Interests, Institutional, Funding: Merck, Amgen, Roche, Sanofi, Pfizer, Boehringer Ingelheim, Sirtex, Servier. S. Stintzing: Non-Financial Interests, Institutional, Invited Speaker: Amgen, AstraZeneca, Bayer, BMS, Esiai, LEO Pharma, Lilly, Merck, MSD, Pierre Fabre, Roche, Sanofi, Servier, Taiho, Takeda; Non-Financial Interests, Institutional, Funding: Merck, Pierre Fabre, Roche, Servier. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.